Company Overview and News

 
Consolidated Zinc intersects thick massive sulphides in Mexico

2017-12-21 proactiveinvestors.com.au
Consolidated Zinc Ltd (ASX:CZL) has intersected thick massive sulphide intervals in extensional and infill resource drilling at its 51% owned Plomosas Project in Mexico.
Upvote Downvote

 
Consolidated Zinc reports first results from Juarez mine

2017-12-04 australianmining.com.au
Consolidated Zinc has reported high-grade zinc results from initial assays at the Juarez mine in Mexico, part of the company’s Plomosas project. Consolidated Zinc acquired a majority share in the long-running zinc-lead-silver project through local subsidiary Minera Latin American Zinc CV SAPI.
Upvote Downvote

 
Consolidated Zinc ramps up Plomosas project

2017-11-15 australianmining.com.au
Australian company Consolidated Zinc is revising its strategy at the Plomosas zinc mine in Mexico following positive scoping study results that confirmed a 100,000-tonne-a-year project.
Upvote Downvote

 
Consolidated Zinc identifies new geophysical target in Mexico

2017-05-24 proactiveinvestors.com.au
Consolidated Zinc (ASX:CZL) has identified a 3 kilometre wide magnetic anomaly from the analysis of geophysical surveys completed over the Plomosas Zinc Lead Silver Project in Mexico.
Upvote Downvote

 
Consolidated Zinc to reveal funding update

2017-04-27 proactiveinvestors.com.au
Consolidated Zinc (ASX:CZL) has been granted a trading halt by the ASX, pending details on a funding update.
Upvote Downvote

 
Consolidated Zinc identifies additional zinc zones in Mexico

2017-03-09 proactiveinvestors.com.au
Consolidated Zinc (ASX:CZL) has identified additional high grade zinc mineralisation from an underground mapping and sampling program at its Plomosas project in Mexico.
Upvote Downvote

 
The zinc price is on the rise, but which companies are set to benefit the most?

2017-01-26 proactiveinvestors.com.au
Balkan Zinc looks set to be the first zinc miner to list in London - if not quite in living memory, then at least in a long, long while.
Upvote Downvote

 
Ivanhoe Mines' exploration geologists receive the 2016 Colin Spence Award for excellence in global mineral exploration for the Flatreef Discovery of platinum-group metals in South Africa

2016-12-08 marketwired
VANCOUVER, BRITISH COLUMBIA--(Marketwired - Dec. 7, 2016) - Robert Friedland, Executive Chairman of Ivanhoe Mines (TSX:IVN)(OTCQX:IVPAF), and Lars-Eric Johansson, Chief Executive Officer, today congratulated Sello Kekana and Dr. David Broughton, two key members of the Ivanhoe Mines exploration team, who have received the prestigious 2016 Colin Spence Award for excellence in global mineral exploration from the Association for Mineral Exploration British Columbia (AME BC).
Upvote Downvote

 
Consolidated Zinc Ltd identifies additional zinc, lead zones at Plomosas

2016-11-15 proactiveinvestors.com.au
The company’s shares were last trading at $0.033, up 22% intraday. The underground drilling and development continued in Level 7 and the newly developed L8.1 testing down plunge extensions from Level 8. The latest assay results include: - 6.55 metres at 13.45% zinc, 7.22% lead, 26.05 g/t silver; - 1.25 metres at 45.80% zinc, 4.03% lead, 38 g/t silver; and - 0.80 metre at 33.30% zinc, 19.50% lead, 89.
Upvote Downvote

 
Consolidated Zinc Ltd intersects massive sulphides at Plomosas Project

2016-10-07 proactiveinvestors.com.au
Consolidated Zinc Ltd (ASX:CZL) has encountered additional intersections of massive and disseminated sulphides from drilling at the Plomosas Zinc Lead Silver Project in Mexico. The underground diamond drilling was designed to test the limits of mineralisation encountered during previous drill programs. Of the 7 completed holes, all have intersected massive sulphide mineralisation of varying widths within broader alteration zones.
Upvote Downvote

 
Consolidated Zinc Ltd intersects massive sulphides at Plomosas Project

2016-10-05 proactiveinvestors.com.au
Consolidated Zinc Ltd (ASX:CZL) has encountered additional intersections of massive and disseminated sulphides from drilling at the Plomosas Zinc Lead Silver Project in Mexico. The underground diamond drilling was designed to test the limits of mineralisation encountered during previous drill programs. Of the 7 completed holes, all have intersected massive sulphide mineralisation of varying widths within broader alteration zones.
Upvote Downvote

 
Consolidated Zinc Ltd to update on Plomosas project

2016-09-26 proactiveinvestors.com.au
Consolidated Zinc Ltd (AS:CZL) has been granted a trading halt by the ASX this morning, pending details on the Plomosas Zinc project. Plomosas is located in Mexico. The halt will remain in place until the opening of trade on Wednesday 28th September 2016, or earlier if an announcement is made to the market.
Upvote Downvote

 
 
Consolidated Zinc Ltd raises $6.5 million from oversubscribed placement

2016-05-09 proactiveinvestors.com.au
Consolidated Zinc Ltd (ASX:CZL) has received firm commitments to raise $6.5 million in new capital to support the ongoing resource drilling at the historic Plomosas Zinc Project in Mexico. It recently acquired a 51% share of the high grade zinc project. A key to the strong demand for CZL stock was the recent successful drill campaign which saw grades in excess of 50% zinc plus lead and significant zinc grades containing 47.
Upvote Downvote

 
Juniors raise $14m

2016-05-06 businessnews.com.au
Listen to podcasts covering breaking news, items of interest and our Success & Leadership Series events. A wide range of topics covered by our well renowned reporters and WA business leaders. Subscribe on iTunes for updates as they happen. Click here for more
Upvote Downvote

Related Articles

GNCA: Genocea Biosciences Analysis and Research Report

2018-04-25 - Asif

Overview Genocea Biosciences is a biopharmaceutical company that discovers and develops novel cancer vaccines. The company use its proprietary discovery platform, ATLAS, to recall a patient’s pre-existing CD4+ and CD8+ T cell immune responses to their tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses. The company believe that using ATLAS to identify antigens for inclusion in cancer vaccines could lead to more immunogenic and efficacious cancer vaccines. In September 2017, the company announced a strategic shift to immuno-oncology and a focus on the development of neoantigen cancer vaccines. Currently, all of its research programs and product candidates in active development are at the preclinical stage. The company's most advanced program is its preclinical immuno-oncology program, GEN-009, a neoantigen cancer vaccine. The GEN-009 program uses ATLAS to identify patient neoantigens, or newly formed anti...

AMZN: Amazon.com, Inc Analysis and Research Report

2018-04-25 - Asif

Overview Amazon.com opened its virtual doors on the World Wide Web in July 1995. The company seek to be Earth’s most customer-centric company. Amazon is guided by four principles: customer obsession rather than competitor focus, passion for invention, commitment to operational excellence, and long-term thinking. In each of its segments, the company serve its primary customer sets, consisting of consumers, sellers, developers, enterprises, and content creators. In addition, the company provide services, such as advertising services and co-branded credit card agreements. Amazon has organized its operations into three segments: North America, International, and Amazon Web Services (“AWS”). These segments reflect the way the Company evaluates its business performance and manages its operations. Additional information on its operating segments and its net sales is contained in Item 8 of Part II, “Financial Statements and Supplementary Data—Note 11—Segment Information.” The compan...

LPCN: Lipocine Inc Analysis and Research Report

2018-04-23 - Asif

Overview Lipocine is a specialty pharmaceutical company focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. The company's proprietary delivery technologies are designed to improve patient compliance and safety through orally available treatment options. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Lipocine has a portfolio of proprietary product candidates designed to produce favorable pharmacokinetic (“PK”) characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. The company's lead product candidate, TLANDO™, is an oral testosterone replacement therapy (“TRT”) and is currently under review by the United States Food and Drug Administration (“FDA”) with a Prescription Drug User Fee Act (“...